Sanara MedTech (SMTI)
NASDAQ:SMTI
Want to see SMTI full AI Analyst Report?
Earnings Data
Report Date
Aug 17, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.23Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a predominantly positive picture: the company delivered strong top-line growth (19% YoY), improved margins, positive GAAP net income, and sizable adjusted EBITDA improvement while expanding commercial reach and reaffirming full-year guidance. Key concerns noted were modest cash reduction, higher interest/other expenses, increased SG&A, and that new sales hires and the Vizient contract will take time to be fully accretive. On balance, the positives (growth, profitability, margin expansion, distribution scale, and cash-based debt servicing) materially outweigh the headwinds.Company Guidance
Strong Revenue Growth
Net revenue increased 19% year-over-year in Q1 2026 (+$4.4M), driven primarily by increased sales of soft tissue repair products including CellerateRX Surgical and BIASURGE.
GAAP Net Profitability Achieved
Broke through to GAAP net income from continuing operations of $0.4 million, or $0.04 per diluted share, compared to a net loss of $0.6 million ($0.07 per diluted share) in Q1 2025.
Margin and Profitability Expansion
Gross profit rose $4.3 million (20%) to $25.9 million and gross margin improved ~100 basis points to 93% of net revenue; operating income increased $1.8 million to $2.6 million.
Adjusted EBITDA Improvement
Adjusted EBITDA increased $1.6 million, or 58%, to $4.3 million in Q1 2026 versus the prior year quarter.
Commercial Footprint and Distribution Expansion
Products are contracted or approved in over 4,000 hospitals and ambulatory surgery centers, sold in over 1,400 facilities (up from >1,300 YoY), and the distribution agreement count grew to >450 from 400 last year.
Sales Force Growth and Market Traction
Sales team expanded to 43 representatives; March marked the strongest sales month in company history (excluding a prior hurricane-related anomaly in Oct 2024).
Confirmed Forward Guidance
Q2 2026 net revenue guidance of $28.5M–$29.5M (10%–14% YoY) and full-year 2026 guidance of $116M–$121M (approx. 13%–17% growth) were reaffirmed.
Improving Capital Allocation and Cash-Flow Discipline
Paid debt service entirely in cash during the quarter (versus prior mix of cash and PIK), cited as a milestone reflecting improved free cash flow generation; capital allocation prioritized organic growth and targeted R&D pipeline investments (e.g., OsStic on track for Q1 2027 market introduction).
SMTI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SMTI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 11, 2026 | $18.02 | $20.44 | +13.43% |
Mar 24, 2026 | $18.34 | $18.08 | -1.42% |
Nov 12, 2025 | $28.04 | $21.11 | -24.71% |
Aug 13, 2025 | $27.47 | $31.92 | +16.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Sanara MedTech (SMTI) report earnings?
Sanara MedTech (SMTI) is schdueled to report earning on Aug 17, 2026, Before Open (Confirmed).
What is Sanara MedTech (SMTI) earnings time?
Sanara MedTech (SMTI) earnings time is at Aug 17, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SMTI EPS forecast?
SMTI EPS forecast for the fiscal quarter 2026 (Q2) is -0.03.